Top Story Today
Vertex Bets $10 Billion That Its Future Isn't Just About Lungs
Vertex Pharmaceuticals paid $85 per share (a 102% premium) to acquire Crinetics Pharmaceuticals for $10 billion in cash, its largest deal ever. The crown jewel: PALSONIFY, an oral pill for acromegaly that replaces the monthly injections patients have endured for decades. Vertex management projects more than $5 billion in combined peak annual revenue from the deal, but it won't be accretive to operating income until 2029. That's three years of patience from a Wall Street crowd that doesn't have much. Shares dipped on the news.
Why it matters: This is Vertex's fifth commercial pillar and its clearest signal yet that it's transforming from a cystic fibrosis specialist into a diversified biotech conglomerate, one mega-deal at a time. If the execution works, it redefines the company. If it doesn't, it's a very expensive pill.
Read more →Deals and Discovery
AstraZeneca Bets $1.5 Billion That AI Can Crack the Liver
AstraZeneca inked a $1.5 billion collaboration with insitro to use machine learning for MASH and cardiomyopathy drug discovery. Only $40 million is upfront; the rest is milestones. It's one of the largest AI-pharma deals ever, and it lands in a disease area that has eaten billions in failed programs. Big pharma isn't flirting with AI anymore. It's writing billion-dollar checks.
Read more →The AI Cancer Startup That Just Talked Wall Street Into $150 Million
Iambic Therapeutics debuted on Nasdaq at $16 per share, raising $150 million in the first real U.S. IPO test for an AI-native cancer biotech. A $670 million AbbVie collaboration announced weeks before the listing didn't hurt. Analysts say the AI label gets attention, but clinical data from lead candidate IAM1363 will determine whether the stock actually goes anywhere.
Read more →Agilent Pays $240M for a Digital Pathology Company Born in a Dorm Room
Proscia, whose cloud-based pathology platform serves 16 of the top 20 pharma companies, is being acquired by Agilent for $240 million (plus $30 million in milestones). The deal gives Agilent an end-to-end pathology stack, from tissue staining to AI-powered digital analysis. Analysts called it a smart price for a company growing above 20%.
Read more →Clinical and Regulatory
What If Your Body Could Build Its Own Cancer-Killing Cells?
The FDA cleared Legend Biotech's LB2501 for U.S. clinical testing, making it the first known dual-targeting in vivo CAR-T therapy to receive an IND. Instead of engineering cells in a factory, LB2501 delivers genetic instructions via IV to reprogram T cells inside the body. Early Chinese data showed a 100% response rate across six patients at the higher dose. Tiny sample, massive implications.
Read more →Anktiva's Bladder Cancer Label Just Got a Lot Bigger
The FDA expanded ImmunityBio's Anktiva label to include high-grade papillary bladder tumors, a large segment of non-muscle invasive bladder cancer cases. The original 2024 approval only covered a narrower subtype. Clinical data showed 62% complete response rates.
Read more →IPF Claims Another Victim, and Syndax's Stock Pays the Price
Syndax's axatilimab failed its Phase 2 trial in idiopathic pulmonary fibrosis, sending shares down roughly 15%. The drug didn't beat placebo on lung function despite testing 145 patients across 14 countries. Syndax abandoned IPF development entirely. The failure casts a shadow over the broader thesis that targeting macrophages via CSF-1R can alter fibrotic lung disease.
Read more →The FDA Just Admitted Its Rare Disease Playbook Needs an Overhaul
The FDA launched its Rare Disease Framework Initiative, acknowledging that applying blockbuster-drug evidence standards to diseases affecting a few hundred people doesn't work. The agency is promising tailored trial designs, innovative statistical methods, and earlier patient input. Orphan drugs made up 52% of all new approvals in 2024, yet most of the 7,000 known rare diseases still lack any treatment.
Read more →Science and Discovery
Arrowhead Found a Way to Quiet the Brain's Most Toxic Protein
Arrowhead's ARO-MAPT silenced the tau gene (Alzheimer's most destructive protein) by 73% in cerebrospinal fluid with just two injections, and the effect lasted at least 90 days after the final dose. It's an RNAi approach that crosses the blood-brain barrier via a simple subcutaneous shot. Biomarker data is striking, but no tau therapy has ever slowed cognitive decline in patients.
Read more →MIT Built Nanoparticles That Reprogram Cancer-Killing Cells Inside the Body
MIT engineers used lipid nanoparticles (the same tech behind mRNA vaccines) to reprogram NK cells directly inside mice, skipping the factory step that makes cell therapy cost upwards of $500,000 per patient. The system hit 80% reprogramming efficiency and worked across melanoma, lymphoma, and autoimmune hepatitis models. This is mouse data, not human proof, but the implications for accessibility are enormous.
Read more →Britain's Bid to Build a Biotech Giant Just Got $310 Million Louder
Oxford spinout OMass Therapeutics raised a $310 million Series C, one of Europe's largest private biotech rounds this year. Bain Capital Life Sciences, Forbion, and Novo Holdings co-led the oversubscribed financing. The cash will push lead program OMS1620 into Phase 2 for congenital adrenal hyperplasia and Cushing's syndrome, testing whether OMass's native mass spectrometry platform can produce real medicines.
Read more →